Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
170 USD | -2.86% |
|
+6.69% | -13.71% |
06-14 | Morgan Stanley Adjusts Price Target on NICE to $240 From $290, Maintains Overweight Rating | MT |
06-12 | RBC Capital Cuts Price Target on NICE to $230 From $265, Maintains Outperform Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With a 2024 P/E ratio at 89.65 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 13.97 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.71% | 10.63B | - | ||
+19.23% | 3,332B | C+ | ||
+19.00% | 93.88B | B | ||
+18.25% | 88.3B | B+ | ||
+45.72% | 55.72B | D+ | ||
-19.16% | 49.9B | B+ | ||
+84.99% | 43.03B | D+ | ||
-34.15% | 40.77B | B- | ||
-2.21% | 27.55B | C+ | ||
-21.48% | 22.98B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NICE Stock
- NCSYF Stock
- Ratings NICE Ltd.